Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREGCorinna Kochanek, Ralf Gutzmer, Yenny Angela et al.|European Journal of Cancer|2023Cited by 7
Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective <scp>DeCOG</scp> registry <scp>ADOReg</scp>Sebastian A. Wohlfeil, Jochen Utikal, Leonie Kranzmann et al.|International Journal of Cancer|2024Cited by 4
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Carmen Loquai, Katharina C. Kähler et al.|Frontiers in Immunology|2025Cited by 4
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Henner Stege, Jochen Utikal et al.|European Journal of Cancer|2025Cited by 4
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna‐Sophia Leven, Selma Ugurel, Triinu Peters et al.|European Journal of Cancer|2025Cited by 4